

VIDEO INTERVIEW

Covid 19 and Cardiovascular Disease

OVERVIEW

COVID-19 infection has created a dramatic health problem worldwide. In addition to respiratory distress, it became immediately apparent that patients with cardiovascular disease were at increased risk for a poor outcome or death from COVID-19. In addition, COVID-19 is able to act directly on cardiac tissue, provoking acute myocarditis. The situation is further complicated by the hypothesis that drugs acting on the renin-angiotensin system might worsen the prognosis in patients with COVID-19 because of the role of ACE2 in modulating cell penetration by the virus. Thus, there is need to discuss in detail the relationship between COVID-19 and cardiovascular disease, including the best therapeutic options to limit the negative cardiovascular consequences of the infection.

LEARNING OBJECTIVES

By viewing this video interview learners will:

- Acquire information about the mechanisms underlying and responsible for the worsening of prognosis in COVID-19 patients with cardiovascular disease.
- Examine the available evidence surrounding RAS-blocker administration and the severity of COVID-19 disease.
- Discuss the best therapeutic approach for cardiovascular disease patients at risk of infection with COVID-19 virus.

TARGET AUDIENCE

This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.



FACULTY

Giuseppe Mancia

Professor Emeritus
University of Milano-Bicocca
Milan, Italy

For information about the program, please contact:

Scientific Seminars International Foundation

T +39 380 1504116 - F +39 06 4827169

info@scientificseminars.com

To access the resource online, click here and login:

<https://www.elearning.scientificseminars.com/the-2020-blended-learning-journey-on-cardiovascular-risks-for-emea/video-interview/>

This educational program is made possible thanks to an independent educational grant received from Merck KGaA, Darmstadt, Germany.